For details, see paragraphs 1-9 and 61-106 of the judgment. At that time, generic manufacturers in order to market their products in the EU needed an originator reference product. After the withdrawal of regulatory approval for the capsule version of Losec, generic manufacturers would no longer be able to market their generic copies of these capsules. Parallel importers of Losec capsules would equally be barred from marketing those.